Table 2_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv حسب Siying Wei (5990276)

"…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …"

Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 1_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv حسب Siying Wei (5990276)

"…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …"

Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 1_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.tiff حسب Siying Wei (5990276)

"…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …"

Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 3_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv حسب Siying Wei (5990276)

"…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …"

Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 4_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.xlsx حسب Siying Wei (5990276)

"…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …"